-
Tavneos Liver Injury Drug Safety Communication Issued by FDA in Late March 2026
Just 2 Months Earlier, Amgen Refused an FDA Request to Withdraw Tavneos; Will There Be a Tavneos Recall Soon? (Posted by Tom Lamb at Drug Injury Watch) On March 31, 2026, the FDA issued a Tavneos liver…
-
Wegovy and Ozempic Vision Loss: Wegovy Rate 5x Higher vs. Ozempic, Men 3x More Often vs. Women
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Semaglutide Study 2026 Data Analysis (Posted by Tom Lamb at Drug Injury Watch) A March 2026 British Journal of Ophthalmology medical journal article, “Ischemic optic neuropathy with semaglutide: global observational analysis…
-
While Rybelsus Pills Are Being Replaced With Pills Called Ozempic, Semaglutide NAION Risk Remains
But the January 2026 Rybelsus-Ozempic Drug Label Still Has No Warnings for NAION Vision Loss Side Effect (Posted by Tom Lamb at Drug Injury Watch) The “Revised: 1/2026” Prescribing Information document for “RYBELSUS and OZEMPIC tablets” caused…
-
Risk of NAION With Semaglutide Medicines is 2 Times Higher Than SGLT2i Diabetes Drugs
2026 Medical Article Links NAION to Ozempic, Wegovy, and Rybelsus, Again, With New Study (Posted by Tom Lamb at Drug Injury Watch) This drug safety issue of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide-containing drugs…
-
Ozempic Tablets and Rybelsus Pancreatitis Side Effects Warnings 2026 Update
Acute Pancreatitis, Including Fatal Hemorrhagic And Necrotizing Pancreatitis – Death Cases (Posted by Tom Lamb at Drug Injury Watch) In October 2025, Rybelsus pancreatitis side effects warnings were added to the Rybelsus “drug label”, and in late…
